According to a new report published by OG Analysis, the global Empty Capsule Market is estimated at USD 4.57 billion in 2026 and is projected to reach USD 9.71 billion by 2034, expanding at a CAGR of 9.87% during the forecast period. The report uses 2025 as its base year and 2026 as the estimated year. The full report, including detailed segmentation, regional analysis.

Market Overview

The market covers the manufacture and supply of hard empty capsules used to encapsulate prescription and OTC medicines, dietary supplements, vitamins and minerals, botanical extracts, probiotics, specialty ingredients, and other oral solid dosage formulations. Capsules are produced from gelatin as well as non-gelatin materials such as hydroxypropyl methylcellulose (HPMC), pullulan, and other plant-based polymers, and are valued for swallowability, flexible dosing, taste and odor masking, and compatibility with high-speed filling operations. Market development is increasingly shaped by vegetarian and clean-label demand, low-moisture formulations for hygroscopic fills, modified-release delivery, capsule-in-capsule concepts, customized colors and printing, anti-counterfeiting features, and stronger supply-chain resilience.

Key Market Insights

●       The market is estimated at USD 4.57 billion in 2026 and is forecast to reach USD 9.71 billion by 2034 at a 9.87% CAGR, supported by pharmaceutical output, nutraceutical consumption, contract manufacturing, and growing preference for convenient oral dosage forms.

●       Nutraceuticals and dietary supplements are a major demand engine, particularly across vitamins, botanicals, probiotics, immunity, gut health, and lifestyle-wellness formulations that benefit from flexible capsule dosing and rapid product launches.

●       HPMC and other non-gelatin capsules are gaining adoption because of vegetarian and clean-label positioning, broader dietary acceptability, lower moisture content, and improved compatibility with hygroscopic or moisture-sensitive fills.

●       Manufacturability on high-speed filling lines is becoming a key supplier-selection criterion, with capsule dimensional consistency, shell strength, static control, defect rates, and technical support directly influencing throughput and yield.

●       Specialty capsule technologies are expanding into enteric delivery, modified-release systems, low-oxygen and low-moisture protection, capsule-in-capsule formats, and other differentiated delivery concepts for complex pharmaceutical and nutraceutical formulations.

Market Dynamics

●       Driver: Rising pharmaceutical production, generic-drug output, nutraceutical consumption, and contract manufacturing are increasing demand for reliable two-piece hard capsule supply across regulated and consumer-health markets.

●       Driver: Consumer preference for vegetarian, vegan, organic, and clean-label dosage forms is accelerating adoption of HPMC, pullulan, and other plant-based capsule materials.

●       Opportunity: Low-moisture capsules, oxygen-barrier shells, enteric delivery, modified-release formats, and capsule-in-capsule technologies create higher-value opportunities for sensitive and differentiated formulations.

●       Restraint: Raw-material quality, gelatin sourcing, polymer costs, colorant restrictions, humidity sensitivity, dimensional tolerances, and regulatory documentation can increase manufacturing complexity and qualification requirements.

●       Restraint: High-volume pharmaceutical and CDMO customers require strong GMP systems, audit readiness, stable lead times, filling-machine compatibility, and multi-site supply continuity, creating high barriers for smaller suppliers.

●       Opportunity: Customization through color, opacity, printing, brand identifiers, anti-counterfeiting features, and traceability can strengthen product differentiation and support private-label and premium supplement brands.

●       Opportunity: Regional manufacturing expansion and dual-sourcing strategies can shorten lead times, reduce logistics risk, and improve supply resilience for customers seeking dependable capsule availability across major markets.

Browse for more information

https://www.oganalysis.com/industry-reports/empty-capsule-market

Market Segmentation

The market is segmented by type, functionality, application, end user, and region. By type, the industry report covers Gelatin Capsules and Non-Gelatin Capsules. By functionality, the market includes Immediate-release Capsules, Sustained-release Capsules, and Delayed-release Capsules. Applications include Antibiotic and Antibacterial Drugs, Dietary Supplements, Antacid and Antiflatulent Preparations, Antianemic Preparations, Anti-inflammatory Drugs, Cardiovascular Therapy Drugs, Cough and Cold Drug Preparations, and Other Therapeutic Applications. End users include the Pharmaceutical Industry, Nutraceutical Industry, Cosmetic Industry, and Research Laboratories. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America.

Regional Insights

●       North America: Demand is supported by high nutraceutical consumption, prescription and OTC solid-dose manufacturing, a large CDMO base, rapid adoption of vegetarian capsules, and strong demand for custom printing, branding, stability, and supply continuity.

●       Asia Pacific: The region is a major growth engine supported by large-scale pharmaceutical and nutraceutical manufacturing, export-oriented production, expanding domestic wellness demand, and rapid scaling of plant-based capsule capacity.

●       Europe: The region is shaped by stringent quality expectations, mature pharmaceutical manufacturing, premium supplements, clean-label positioning, sustainability, HPMC adoption, and strong emphasis on audit-ready supply chains and product documentation.

●       Latin America & Middle East and Africa: These regions offer developing opportunities through expanding supplement consumption, local pharmaceutical production, distributor-led access, halal-friendly and vegetarian capsule demand, and gradual growth of regional contract manufacturing.

Competitive Landscape

The market is concentrated around a limited number of large global capsule manufacturers, regional producers, and specialty innovators. Competitive positioning depends on production scale, shell consistency, filling-machine performance, material innovation, GMP compliance, regulatory audit history, customization, technical service, and secure supply. Global suppliers are expanding plant-based and specialty capsule portfolios, while investment in localized production and digital manufacturing is becoming more important as customers seek shorter lead times, supply resilience, and consistent performance across multiple filling sites.

Some of the key players operating in the market include Lonza Group, ACG Worldwide, Qualicaps, Suheung Co. Ltd., CapsCanada Corporation, Bright Pharma Caps, Medi-Caps Ltd., Natural Capsules Limited, Anhui Huangshan Capsule Co. Ltd., Snail Pharma Industry Co. Ltd., Shangxi JC Biological Technology Co. Ltd., Rottendorf Pharma, and Gelita AG.

Recent Developments

●       July 2026: ACG showcased its connected oral-solid-dose manufacturing portfolio at Pharma Pro&Pack Expo, including the ZR1P high-performance encapsulation machine designed for compact, automated capsule filling with precise weight control and gentle pellet handling.

●       May 2026: ACG presented its fully vegan capsule system at Vitafoods Europe 2026, highlighting ACGcaps H+, a thermogelled HPMC capsule made from cellulose and water with no added gelling agents, alongside plant-based pigments and vegan printing options.

●       March 2026: Lonza signed an agreement to divest its Capsules & Health Ingredients business to Lone Star Funds for an enterprise value of CHF 2.3 billion, with Lonza retaining a 40% equity position in the capsule and health-ingredients business.

●       October 2025: ACG announced a USD 200 million phased investment to establish its first U.S. hard-shell capsule manufacturing operations, including dedicated gelatin and HPMC capacity in Atlanta with operations targeted for early 2027.

●       October 2025: Lonza Capsugel launched Organicaps, the first USDA organic-certified, plant-based immediate-release pullulan capsule manufactured in North America, targeting organic nutraceutical formulations requiring high oxygen barrier and clean-label positioning.